PrEP 201

Target Audience

This activity is intended for current preexposure prophylaxis (PrEP) providers specializing in infectious disease, HIV, and sexual health, as well as primary care, internal medicine, obstetrician-gynecologist, and pediatric physicians, physician assistants, nurse practitioners, and nurses.

Program Overview

This advanced activity is designed for clinicians who are already prescribing PrEP and are seeking to refine their practice in response to evolving clinical scenarios and patient needs. Topics include strategies for engaging underserved populations affected by social determinants of health, medical mistrust, and trauma, as well as guidance on switching between PrEP regimens based on individual patient factors. Learners will gain practical insights for optimizing long-acting injectable (LAI) PrEP implementation, including clinic workflow, injection technique, and resistance prevention. The activity also explores barriers to adherence and persistence, particularly among women and adolescents, and reviews emerging PrEP options currently under investigation. Through evidence-based strategies and real-world considerations, experienced providers will enhance their ability to deliver patient-centered, flexible HIV prevention care.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Engage underserved patient populations in starting and adhering to PrEP regimens
2. Employ guideline-directed protocols for patients wishing to switch between PrEP regimens
3. Implement LAI PrEP provision into clinic workflow, including treatment initiation, monitoring, and follow-up care
4. Describe clinical evidence for new PrEP options in late-stage development, including safety, efficacy, and administration protocols

Faculty

Colleen F. Kelley, MD, MPH
Professor of Medicine
Division of Infectious Diseases
Emory University
Atlanta, Georgia

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must score at least 75% on the posttest and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty has the following relevant financial relationships with ineligible companies:

Colleen F. Kelley, MD, MPH: Contracted Research: Gilead Sciences, Inc., Merck, Moderna, Novavax, ViiV

The planners and managers at Integritas Communications have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.